113 related articles for article (PubMed ID: 17350320)
1. Treating patients with Gaucher disease and parkinsonism: misrepresentation in a title.
Goker-Alpan O; Sidransky E
Parkinsonism Relat Disord; 2008; 14(1):81-2; author reply 83. PubMed ID: 17350320
[No Abstract] [Full Text] [Related]
2. Imino sugar therapy for type 1 Gaucher disease.
Priestman DA; Platt FM; Dwek RA; Butters TD
Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
[No Abstract] [Full Text] [Related]
3. [Organization of Gaucher disease management in France].
Stirnemann J; de Villemeur TB; Belmatoug N
Rev Med Interne; 2007 Oct; 28 Suppl 2():S198-201. PubMed ID: 18228688
[TBL] [Abstract][Full Text] [Related]
4. Gaucher disease: improving management.
Bembi B; Deegan P
Acta Paediatr; 2008 Apr; 97(457):81-2. PubMed ID: 18339194
[No Abstract] [Full Text] [Related]
5. Gaucher disease: hematologic and oncologic implications.
Hughes D
Clin Adv Hematol Oncol; 2011 Oct; 9(10):771-2. PubMed ID: 22252578
[No Abstract] [Full Text] [Related]
6. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
[No Abstract] [Full Text] [Related]
7. Gaucher disease due to saposin C deficiency, previously described as non-neuronopathic form--no positive effects after 2-years of miglustat therapy.
Tylki-Szymańska A; Groener JE; Kamiński ML; Ługowska A; Jurkiewicz E; Czartoryska B
Mol Genet Metab; 2011 Dec; 104(4):627-30. PubMed ID: 21978771
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Gaucher's disease with OGT 918.
Mistry PK
Lancet; 2000 Aug; 356(9230):676-7. PubMed ID: 10968454
[No Abstract] [Full Text] [Related]
9. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
Hachulla E; Javier RM
Rev Med Interne; 2007 Oct; 28 Suppl 2():S180-2. PubMed ID: 18228685
[No Abstract] [Full Text] [Related]
10. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat.
Hughes DA; Ginsberg L; Baker R; Goodwin S; Milligan A; Richfield L; Mehta AB
Parkinsonism Relat Disord; 2007 Aug; 13(6):365-8. PubMed ID: 17049454
[TBL] [Abstract][Full Text] [Related]
11. [New data on Gaucher's disease].
Stirnemann J
Rev Med Interne; 2008 Mar; 29(3):176-8. PubMed ID: 17964006
[No Abstract] [Full Text] [Related]
12. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Pastores GM; Elstein D; Hrebícek M; Zimran A
Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
[TBL] [Abstract][Full Text] [Related]
13. Gaucher disease: unmet treatment needs.
Mehta A
Acta Paediatr; 2008 Apr; 97(457):83-7. PubMed ID: 18339195
[TBL] [Abstract][Full Text] [Related]
14. Overcoming the Next Barriers to Successful Therapy.
Cohen IJ; Baris H; Mistry PK; Sands MS
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():629. PubMed ID: 27491209
[No Abstract] [Full Text] [Related]
15. Computerized cognitive testing in patients with type I Gaucher disease: effects of enzyme replacement and substrate reduction.
Elstein D; Guedalia J; Doniger GM; Simon ES; Antebi V; Arnon Y; Zimran A
Genet Med; 2005 Feb; 7(2):124-30. PubMed ID: 15714080
[TBL] [Abstract][Full Text] [Related]
16. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
Camou F; Viallard JF
Blood Cells Mol Dis; 2012 Jan; 48(1):51-2. PubMed ID: 21983348
[No Abstract] [Full Text] [Related]
17. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
Javier RM; Hachulla E
Presse Med; 2007 Dec; 36(12 Pt 3):1971-84. PubMed ID: 17498916
[TBL] [Abstract][Full Text] [Related]
18. Risks of Gaucher's treatment.
Barranger JA
Lancet; 2000 Oct; 356(9238):1353-4. PubMed ID: 11073045
[No Abstract] [Full Text] [Related]
19. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
Hollak CE; Hughes D; van Schaik IN; Schwierin B; Bembi B
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of the French cohort of Gaucher disease patients].
Stirnemann J
Rev Med Interne; 2006 Mar; 27 Suppl 1():S18-21. PubMed ID: 16644396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
